glp-1 for metabolic syndrome Emerging Role of Receptor Agonists the Treatment of MASH Why are GLP-1 agonists being

Clinical response: Reach out to patients, work to address barriers, and provide motivational support or technical assistance

Unlike injections, which can be given at any time, there are fairly strict oral GLP-1 fasting requirements

A small observational study published in JCI Insight (2022) examined individuals with obesity receiving semaglutide who reported reductions in alcohol intake, though the relationship to weight loss requires further investigation in controlled trials

The large share of this segment can be attributed to the growing adoption of Ozempic (semaglutide), The diabetes segment dominated the overall GLP-1 agonists market in 2024